MIRA Pharmaceuticals, Inc. MIRA
At closeNov 11, 2026, 4:00 PM EST
After hours · Nov 11, 4:00 PM ET
- YTD
- -58.80%
- 1 year
- -57.10%
- Market cap
- 26.14M
- EPS (ttm)
- -1.14
- Shares out
- 16.56M
- Forward P/E
- -2.14
- YTD return
- -58.80%
- 1-year return
- -57.10%
- Volume
- 52.55K
- Avg volume
- 602.51K
- Open
- 0.62
- Previous close
- 0.6209
- Day's range
- 0.6027 – 0.63
- 52-week range
- 0.51 – 1.69
- Analysts
- Strong Buy
- Price target
- 12.08 (+1842.3%)
- Earnings date
- Aug 13, 2024
Key statistics
- Enterprise value
- 20.23M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 3.55
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -4.45M
- Total cash
- 2.82M
- Total debt
- 0
- Return on equity
- -748.59%
- Short % of float
- 10.30%
- 50-day average
- 1.35
- 200-day average
- 1.25
Analyst view
Consensus: strong buy
- Target (low)
- 7.50
- Target (mean)
- 12.08
- Target (high)
- 17.75
- Strong buy0
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 13, 2024
Expected Aug 13, 2024. Consensus EPS estimate -0.22.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.18 | -0.14 | +0.04 | +22.22% |
| Aug 13, 2024 | Jun 1, 2024 | -0.10 | — | — | — |
| Aug 13, 2024 | Jun 1, 2024 | -0.10 | -0.11 | -0.01 | -10.00% |
| May 13, 2024 | Mar 1, 2024 | -0.10 | — | — | — |
| May 13, 2024 | Mar 1, 2024 | -0.10 | -0.12 | -0.02 | -20.00% |
| Nov 13, 2023 | Sep 1, 2023 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 30, 2024 | Rodman & Renshaw | init | — | Buy |
| Aug 5, 2024 | Ascendiant Capital | init | — | Buy |
About MIRA Pharmaceuticals, Inc.
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- United States
- Website
- mirapharmaceuticals.com
News
MIRA Pharmaceuticals Announces Its Data From Exploratory Pilot Of SKNY-1 Shows Reductions In Body Weight, Fat Mass 
MIRA Pharmaceuticals Reports Significant Weight and Fat Reduction With Oral SKNY-1 in Obese Mice, Showing Favorable Lean-Mass and Weight-Regain Outcomes Compared With Semaglutide 
MIRA Pharmaceuticals Announces Initial Proof-Of-Concept Results From Pilot Study Of SKNY-1 For Obesity And Metabolic Disorders In A Diet-Induced Obesity Mouse Model; Study Demonstrated Statistically Significant Reductions In Body Weight And Fat Mass Following Oral Administration Of SKNY-1 Compared With Vehicle-Treated Controls 
MIRA Pharma Reports 21-Day Preclinical Proof-Of-Concept Study Showing That Once-Daily Oral MIRA-55 Significantly Reduced Mechanical And Thermal Pain Hypersensitivity; Results Back MIRA-55's Progress Toward IND Filing 
MIRA Pharmaceuticals Reports MIRA-55 Demonstrated Significant Pain Relief Comparable to Celebrex in Chronic Inflammatory Pain Study 
12 Health Care Stocks Moving In Monday's After-Market Session 
12 Health Care Stocks Moving In Friday's After-Market Session 
Maxim Group Initiates Coverage On Mira Pharmaceuticals with Buy Rating, Announces Price Target of $3.5 - MIRA Pharmaceuticals Submits Phase 2a Ketamir‑2 Protocol For CIPN To IRB, Incorporating FDA Feedback And Targeting Q1 2027 Site Initiation
MIRA Pharmaceuticals Advances Ketamir-2 to Phase 2a in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Following FDA Review
Your note
Sign in to keep a note on MIRA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AMINOV EREZ | Chief Executive Officer | Sale | Nov 19, 2024 | 1,061,200 |
| CAPPY GEORGE | Beneficial Owner of more than 10% of a Class of Security | Purchase | Aug 6, 2023 | 0 |
| MCNULTY BRIAN PATRICK | Beneficial Owner of more than 10% of a Class of Security | Sale | Aug 27, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Cross Staff Investments Inc. | 2.21% | 365,901 | 384.20K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.70% | 115,914 | 121.71K | Sep 29, 2024 |
| Suncoast Equity Management | 0.54% | 90,000 | 94.50K | Sep 29, 2024 |
| LPL Financial LLC | 0.30% | 50,000 | 52.50K | Sep 29, 2024 |
| Schonfeld Strategic Advisors Llc | 0.25% | 41,900 | 43.99K | Sep 29, 2024 |
| Millennium Management Llc | 0.25% | 40,725 | 42.76K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.36% | 60,374 | 63.39K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.13% | 21,893 | 22.99K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.10% | 16,184 | 16.99K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.06% | 9,455 | 9.93K | Oct 30, 2024 |